We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

130 hedge funds and large institutions have $2.77B invested in MoonLake Immunotherapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 37 increasing their positions, 52 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more capital invested

Capital invested by funds: $2.34B → $2.77B (+$434M)

5% more call options, than puts

Call options by funds: $39.6M | Put options by funds: $37.7M

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2.06% less ownership

Funds ownership: 94.65% → 92.59% (-2.1%)

4% less funds holding

Funds holding: 136 → 130 (-6)

15% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 27

29% less repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 52

Holders
130
Holders Change
-6
Holders Change %
-4.41%
% of All Funds
1.71%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
23
Increased
37
Reduced
52
Closed
27
Calls
$39.6M
Puts
$37.7M
Net Calls
+$1.9M
Net Calls Change
-$10.4M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$56.2M
2
RI
RTW Investments
New York
+$30.2M
3
SL
Siren LLC
Connecticut
+$20.7M
4
VPC
Vestal Point Capital
New York
+$14.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$14M

Top Sellers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
-$34.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$24.3M
3
CCM
Camber Capital Management
Massachusetts
-$17.2M
4
FC
Finepoint Capital
Massachusetts
-$17M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$14.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$11.6M -$5.98M -146,810 -37%
Ameriprise
27
Ameriprise
Minnesota
$9.46M -$48.9K -1,200 -0.6%
LGM
28
Logos Global Management
California
$9.44M -$6.11M -150,000 -43%
IHAM
29
Integral Health Asset Management
New York
$9.44M – – –
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$8.81M +$7.6M +186,568 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$8.79M -$1.25M -30,752 -14%
DC
32
Decheng Capital
California
$8.57M +$407K +10,000 +6%
CCM
33
Catalio Capital Management
New York
$7.67M +$1.95M +47,980 +42%
OCA
34
Octagon Capital Advisors
New York
$6.99M -$6.03M -148,000 -50%
Pictet Asset Management
35
Pictet Asset Management
Switzerland
$6.97M -$7.1M -174,393 -54%
CS
36
Candriam SCA
Luxembourg
$6.84M -$1.21M -29,690 -17%
RHJA
37
Rice Hall James & Associates
California
$6.72M +$196K +4,804 +3%
Victory Capital Management
38
Victory Capital Management
Texas
$6.53M -$4.88M -119,782 -46%
Vanguard Group
39
Vanguard Group
Pennsylvania
$5.71M +$279K +6,851 +6%
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5.19M -$608K -14,935 -12%
Hudson Bay Capital Management
41
Hudson Bay Capital Management
Connecticut
$4.96M +$1.02M +25,000 +31%
Axa
42
Axa
France
$3.96M -$823K -20,205 -19%
SCM
43
Silverarc Capital Management
Massachusetts
$3.87M +$3.34M +82,023 New
GIM
44
Granahan Investment Management
Massachusetts
$3.79M -$2.52M -61,858 -43%
UBS Group
45
UBS Group
Switzerland
$3.79M -$1.65M -40,419 -33%
CAM
46
Congress Asset Management
Massachusetts
$3.44M +$4.93K +121 +0.2%
State Street
47
State Street
Massachusetts
$3.05M -$1.17M -28,833 -31%
Jennison Associates
48
Jennison Associates
New York
$2.94M +$2.54M +62,318 New
Geode Capital Management
49
Geode Capital Management
Massachusetts
$2.81M +$22.8K +559 +0.9%
MAP
50
Moody Aldrich Partners
Massachusetts
$2.57M -$33.8K -829 -2%
1
2
3 4 5

MLTX Hedge Fund Activity: Q2 2025 in Review

130 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q2 2025, worth a combined $2.77B — up 19% from $2.34B a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of MLTX and 23 opened new positions — a net loss of 4 holders — while 52 trimmed existing stakes and 37 added.

The largest buyer was Avoro Capital Advisors, adding an estimated $56.2M. The largest seller was Polar Capital Holdings, cutting an estimated $34.7M.

  • 130 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q2 2025, down from 136 in Q1 2025.
  • Funds reported $2.77B of MoonLake Immunotherapeutics stock for Q2 2025, up 19% quarter-over-quarter.
  • 23 funds opened new MoonLake Immunotherapeutics positions in Q2 2025 and 27 closed out, a net change of -4 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q2 2025 was Avoro Capital Advisors, an estimated $56.2M added.
  • The largest MoonLake Immunotherapeutics seller in Q2 2025 was Polar Capital Holdings, an estimated $34.7M sold.

Based on aggregated 13F filings for Q2 2025.